Compare stocks

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company based in Lainate, Italy, focusing on the development and manufacturing of products for specific gastrointestinal diseases. The company's core business involves oral therapies, particularly for conditions such as inflammatory bowel disease and colon cancer. Notable products include Lialda/Mezavant, a treatment for ulcerative colitis, and Eleview, a medical device used in endoscopic procedures. Cosmo Pharmaceuticals leverages proprietary drug delivery technologies to enhance treatment efficacy and patient compliance. While headquartered in Italy, it operates primarily within the European market and maintains a strategic partnership network to expand its global reach.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.